摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苯并二氢吡喃-3-胺盐酸盐

中文名称
苯并二氢吡喃-3-胺盐酸盐
中文别名
——
英文名称
3,4-dihydro-2H-1-benzopyran-3-amine hydrochloride
英文别名
3,4-dihydro-2H-chromen-3-amine;hydron;chloride
苯并二氢吡喃-3-胺盐酸盐化学式
CAS
——
化学式
C9H11NO*ClH
mdl
MFCD01736331
分子量
185.653
InChiKey
NSLATPDKWVAAIL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.12
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    苯并二氢吡喃-3-胺盐酸盐 以56%的产率得到
    参考文献:
    名称:
    SARDA N.; GROUILLER A.; PACHECO H., EUR. J. MED. CHEM., 1976, 11, NO 3, 251-256
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    SARDA N.; GROUILLER A.; PACHECO H., EUR. J. MED. CHEM., 1976, 11, NO 3, 251-256
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
    申请人:Merck Patent GmbH
    公开号:US20160168090A1
    公开(公告)日:2016-06-16
    The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    本发明涉及吲哚化合物及其药用可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
  • Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
    申请人:Gomtsyan Arthur
    公开号:US20060128689A1
    公开(公告)日:2006-06-15
    Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
    对VR1受体拮抗剂,其化学式为(I)或其药用可接受的盐、前药或前药的盐,其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述,并且在通过抑制VR1受体预防或改善的疾病中具有用处。
  • [EN] 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS DE L'ACIDE CARBOXYLIQUE PHÉNOXYCHROMANE SUBSTITUÉS EN 6
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2009158426A1
    公开(公告)日:2009-12-30
    Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    式(I)的化合物:其中A1、A2、W、L、G、R7a、R7b、R8、R9和R10具有规范中给定的含义,是DP2受体调节剂,可用于治疗免疫性疾病。
  • 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders
    申请人:Soares Da Silva Patricio Manuel Vieira Araújo
    公开号:US20100286219A1
    公开(公告)日:2010-11-11
    A method comprising utilizing a compound of formula I: where R 1 , R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R 4 signifies hydrogen, alkyl or alkylaryl group; X signifies CH 2 , oxygen atom or sulphur atom; n is 1, 2 or 3, with the proviso that when n is 1, X is not CH 2 ; and the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyloxy, halogen or nitro group; the term halogen means fluorine, chlorine, bromine or iodine, in the manufacture of a medicament for the treatment of one or more of the following indications: congestive heart failure, angina, arrhythmias, circulatory disorders, Raynaud's Phenomenon, migraine, and anxiety disorders.
    一种方法包括利用式I的化合物:其中R1,R2和R3相同或不同,并表示氢,卤素,烷基,烷基芳基,烷氧基,羟基,硝基,氨基,烷基羰基氨基,烷基氨基或二烷基氨基基团;R4表示氢,烷基或烷基芳基基团;X表示CH2,氧原子或硫原子;n为1,2或3,但当n为1时,X不是CH2;以及(R)-和(S)-对映体或对映体的混合物及其药学上可接受的盐;其中术语烷基表示含有一至六个碳原子的碳氢链,直链或支链,可选地被芳基,烷氧基,卤素,烷氧羰基或羟基羰基基团取代;术语芳基表示苯基或萘基,可选地被烷氧基,卤素或硝基取代;术语卤素表示氟,氯,溴或碘,在制备用于治疗以下一种或多种适应症的药物:充血性心力衰竭,心绞痛,心律失常,循环障碍,雷诺现象,偏头痛和焦虑症。
  • Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
    申请人:Portela & C.A., S.A.
    公开号:US20040142996A1
    公开(公告)日:2004-07-22
    Compounds of formula I: t,0010 where R 1 , R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R 4 signifies hydrogen, alkyl or alkylaryl group; X is CH 2 , O or S, and n is 1, 2 or 3, with the proviso that if X is CH 2 , n is not 1, and a method for their preparation. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.
    式I的化合物:其中R1、R2和R3相同或不同,表示氢、卤素、烷基、烷基芳基、烷氧基、羟基、硝基、氨基、烷基羰基氨基、烷基氨基或二烷基氨基基团;R4表示氢、烷基或烷基芳基基团;X为CH2、O或S,n为1、2或3,但如果X为CH2,则n不为1;以及它们的制备方法。这些化合物具有潜在的有价值的药理特性,可用于治疗心血管疾病,如高血压和慢性心力衰竭。
查看更多